1 **Cost-effectiveness of WHO Problem Management Plus for adults impaired by psychological**
2 **distress in a post-conflict setting of Pakistan**

3

4 Syed Usman Hamdani, Ph.D., University of Liverpool, UK & Human Development Research

5 Foundation, Islamabad, Pakistan

6 Zill-e-Huma, MPH, Human Development Research Foundation, Islamabad, Pakistan

7 Atif Rahman, Ph.D., University of Liverpool, Liverpool, UK

8 Duolao Wang, PhD, Liverpool School of Tropical Medicine, UK

9 Tao Chen, PhD, Liverpool School of Tropical Medicine, UK

10 Mark van Ommeren, Ph.D., Department of Mental Health and Substance Abuse, World Health

11 Organization, Geneva, Switzerland

12 Dan Chisholm, Ph.D., WHO Regional Office for Europe; Copenhagen, Denmark

13 Saeed Farooq, Ph.D., Lady Reading Hospital, Peshawar, Pakistan and Research Institute for Primary

14 Care & Health Sciences, Keele University, UK

15 **Corresponding Author:**
16 Syed Usman Hamdani
17 Human Development Research Foundation,
18 House No# 6, street 55, F-7/4 Islamabad,
19 44000 Pakistan.
20 E: s.u.hamdani@liverpool.ac.uk
21

22 **Word count (except abstract): 3497**

23

24

25

26

27

21

28 **Author contribution:**

29 Hamdani, Zill-e-Huma, Chen and Wang had full access to all of the data in the study and take
30 responsibility for the integrity of the data and the accuracy of the data analysis.

31 **Concept and design:** Hamdani, Rahman, Farooq, Chisholm, van Ommeren.

32 **Acquisition, analysis, or interpretation of data:** Hamdani, Zill-e-Huma, Wang, Farooq, van
33 Ommeren, Chisholm

34 **Drafting of the manuscript:** Hamdani, Zill-e-Huma, Rahman, van Ommeren, Chisholm, Farooq

35 **Critical revision of the manuscript for important intellectual content:** Hamdani, Zill-e-Huma,
36 Rahman, Farooq, Chisholm, Chen, Wang, van Ommeren.

37 **Statistical analysis:** Hamdani, Zill-e-Huma, Chisholm, Chen, Wang

38 **Obtained funding:** van Ommeren, Rahman, Hamdani.

39 **Administrative, technical, or material support:** Hamdani, Zill-e-Huma, Rahman, Farooq, van
40 Ommeren.

41 **Study supervision:** Hamdani, Rahman, Farooq, van Ommeren.

57 **Disclaimer**

21

61   **Competing interests**

62   All authors have declared no conflicts of interest.

63

64

ABSTRACT

Background

With the development of evidence-based interventions for treatment of priority mental health conditions in humanitarian settings, it is important to establish the cost-effectiveness of such interventions to enable their scale-up.

Aims

To evaluate the cost-effectiveness of Problem Management Plus (PM+) intervention, compared to Enhanced Usual Care (EUC) for common mental disorders in primary healthcare in Peshawar, Pakistan.

Methods

We randomly allocated 346 participants to either PM+ (n=172) or EUC (n=174). Effectiveness was measured using Hospital Anxiety and Depression Scale (HADS) at 3 months' post-intervention. Cost-effectiveness analysis was performed as incremental costs (measured in Pakistani Rupees [PKR] per unit change in anxiety, depression and functioning scores.

Results

The total cost of delivering PM+ per participant was estimated at PKR 16,967 (US $ 163.14) using an international master trainer and supervisor, and PKR 3,645 (US$35.04; US$ 7 per session) employing a national trainer. The mean cost per unit score improvement in anxiety and depression symptoms on HADS was PKR 2957 (95% CI: 2262, 4029) [US$ 28] with international trainer/supervision and PKR 588 (95% CI: 434, 820) or US$ 6 with local trainer/supervisor. The mean Incremental Cost-Effectiveness Ratio (ICER) to successfully treat a case of depression (PHQ-9 $\geq$ 10) using an international supervisor was PKR 53,770 (95% CI: 39,394, 77,399) [US$ 517] versus a local supervisor PKR 10,705 (95% CI: 7731, 15,627) [US$ 102.93].

Conclusions

The PM+ was more effective but also more costly than EUC in reducing symptoms of anxiety, depression and improving functioning in adults impaired by psychological distress in a post-conflict setting of Pakistan.

Key words: Cost-effectiveness, lay health workers, Low and Middle Income Countries (LMIC), humanitarian settings, Problem Management Plus, Common Mental Disorders (CMDs)

Trial Registration anzctr.org.au Identifier: ACTRN12614001235695

21

103   Mental health problems cause a significant burden of disease in Low and Middle Income Countries

104   (LMICs), yet the documented 'mental health treatment gap' is up to 90% [1-3]. The need for mental

105   health services is much greater in populations affected by humanitarian crises. More than 135 million

106   people are in need of humanitarian assistance due to ongoing humanitarian crises and conflicts globally

107   [4]. A systematic review and meta-analysis of mental health outcomes in population affected by conflict

108   and displacements showed that mood and anxiety disorders were common, with rates of 17.3% for

109   depression and 15.4% for posttraumatic stress disorder [5]. Epidemiological studies from areas affected

110   by humanitarian crises in Pakistan found high rates of psychological distress in these populations. One

111   study reported rates as high as 38% to 65% for psychological distress in women [6, 7]. Majority of

112   people have no access to mental health services in such settings [6]. Over the past decade, significant

113   progress has been made in terms of availability of evidence based mental health intervention packages

114   for populations affected by humanitarian crises [8]. However, sustainability and scalability of such

115   psychological interventions remains a challenge in populations affected by humanitarian crises in low

116   resource settings globally [9].

117   We developed and tested a brief, multicomponent behavioural intervention, Problem Management Plus

118   (PM+) delivered by lay health workers for Common Mental Disorders (CMDs) in conflict affected

119   settings. The intervention was effective for treating the symptoms of CMDs in a post-conflict setting

120   of Pakistan. Trial protocol and results of pilot and definitive clinical trials have been published [10-12].

121   In the present study, we conduct an economic evaluation alongside the randomized controlled trial to

122   assess the cost-effectiveness of this intervention in order to inform policy and implementation in routine

123   clinical practice.

124   **Method**

125   **Study site and participants**

126   Participants included 346 primary care attendees with high level of psychological distress (score above

127   2 on General Health Questionnaire [GHQ-12]) [13] and functional impairment (score above 16 on

128   World Health Organization Disability Assessment Schedule 2.0 [WHODAS 2.0]) [14]. The participants

129   were individually randomized in 1:1 ratio to either intervention arm i.e. PM+ (n=172) along with

130   Enhanced Usual Care (EUC)) or the Control arm consisting of Enhanced Usual Care (EUC) only

131   (n=174). The study was approved locally by the Institutional Review and Ethics Board of the

21

132 Postgraduate Medical Institute, Lady Reading Hospital, Peshawar, and by the WHO Ethical Review

133 Committee. Written informed consent was obtained from all study participants.

134 **The Intervention**

135 Participants in the intervention arm received a brief multicomponent intervention called Problem

136 Management Plus (PM+) [15]. The intervention is trans-diagnostic as it applies the same underlying

137 principles across mental disorders, without tailoring the protocol to specific diagnoses [16]. PM+ is

138 based on well-established principles of problem solving and behavioural techniques. It is designed to

139 be used for adults experiencing common mental health problems (e.g. anxiety, stress, depression and

140 grief) only. It is not suitable for the treatment of severe mental health problems (including psychosis or

141 risk for suicide). Both an individual and group version of the intervention exists. The current study

142 involves the individual version.

143 PM+ consists of 5 weekly face-to-face sessions of 90 minutes each, delivered by trained lay health

144 workers. The intervention is composed of four core strategies i.e. stress management, managing

145 problems, get going, keep doing (behavioural activation), strengthening social support, introduced

146 sequentially in the intervention sessions. In the last session, all the strategies are reviewed with a

147 particular emphasis on using these strategies for self-management in the future and to prevent relapse.

148

149 Training and supervision followed a cascade model. An international master trainer trained local

150 trainers in a 6-day training workshop. Training consisted of intervention delivery, training and

151 supervision skills. Local trainers cascaded the training to lay health workers (with 12-16 year of

152 education) in an 8-day training. Lay health workers were provided weekly supervision by local

153 trainers/supervisors (hereafter local supervisor) who were in turn, supervised monthly by the

154 international master trainer/supervisor (hereafter international supervisor) via video conference for 2

155 to 3 hours. The intervention is available in Urdu and English on the WHO website [17]. Further details

156 of intervention are described elsewhere [15].

157 **Enhanced care as usual**

158 The participants in both intervention arm and control arm received Enhanced Usual Care (EUC). The

159 treatment was enhanced as the Primary Health Care (PHC) physicians in the participating primary

160 health care centres received a 5-day training in the management of Common Mental Disorders (CMDs)

21

in primary health care settings. The training was reinforced through a one-day refresher training for the primary health care physicians. The study participants in both arms were able to seek other health care services from their PHC physicians.

Data Collection

A. Health outcomes

The outcomes were measured at baseline and 3 months' post-intervention. The cost-effectiveness analysis was performed as incremental costs per unit change in anxiety, depression and functioning scores. The primary outcome was change in symptoms of anxiety and depression measured with the Hospital Anxiety and Depression Scale (HADS) [18, 19]. Severity of symptoms was measured using the -HADS-Anxiety (anxiety; 7 items; possible score range, 0-21) and Depression (depression; 7 items; possible score range, 0-21). Higher scores indicate more anxiety and/or depression. Secondary outcomes were functional impairment and presence of depressive disorders. WHODAS-12 was used to assess functional impairment. Polytomous scoring algorithm of WHODAS-12 was used to transform the functional impairment scores on a scale of 1-100[14]. Presence of depressive disorder was measured using a 9-item Patient Health Questionnaire (PHQ-9) [20]. Other secondary outcome measure included PCL-5 [21], results of which are attached as a web appendix.

B. Health resource use profiling

The data on health resource use was collected using the Client Services Receipt Inventory (CSRI) [22], which records the clients' contact with out-patient services (i.e. mental health specialist, general physician, traditional healer, community health workers etc.), inpatient (hospital admissions) services and out of pocket costs associated with travel, medications and tests/investigations during the preceding recall period. A section on seeking religious help and retreats was added to adapt the tool for use in local population. Study participants self-reported their health-care utilization, medication use and out-of-pocket expenditures on CSRI [22] at baseline and 3-months' post-intervention.

C. Cost measurement and analysis

Economic analysis was conducted primarily from a health system perspective, consisting of a) costs incurred over the trial period in the delivery of the intervention itself, b) use of other healthcare and

21

190 related services by study participants, including religious help and retreats, and c) patient and family

191 costs (such as number of days with reduced working hours, informal caregiving time by relatives or

192 friends as well as travel costs and time spent travelling to or waiting for consultations). No discounting

193 of costs was applied since the study was performed within one year.

194

195 *Intervention costs:* These included costs for the intervention adaptation workshops, translations of

196 intervention manual and training materials; printing of adapted training manuals, staff recruitment,

197 training and supervision. Supervision costs included time spent by master trainer, supervisors, transport

198 costs for fieldwork supervision, and costs of all other resources used.

199

200 To estimate the cost of intervention delivery, we evaluated unit cost per minute of health care providers'

201 time including the international master trainer/supervisor, local supervisors, lay health workers and

202 physicians. The unit cost per minute was multiplied with the total estimated time spent by each health

203 care provider to the participants to calculate the total cost of intervention delivery. We calculated the

204 cost of intervention delivery with the international master trainer/supervisor and modelled the cost for

205 a local supervisor as a potentially more sustainable way to support task-shifting in low resource settings.

206 Costs of the intervention were calculated by multiplying the total contact time (number of minutes) a

207 participant had in the intervention arm with a lay health worker by the per-minute cost of the lay health

208 workers' time and the costs spent on travelling by lay health workers (unit cost calculations are

209 provided as web appendix).

210

211 Calculation of these intervention costs as well as contacts with a range of formal health care providers

212 was facilitated by the use of a simplified costing template for unit cost calculations reported in health

213 economic evaluation of mental health services [23]. Unit cost templates accounted for the costs of

214 salaries of staff employed in the provision of intervention delivery (including master trainer,

215 supervisors, lay health workers and PHC staff), facility operating costs where the service was provided,

216 overhead costs relating to the provision of service (personnel, finance etc.) and the capital costs of the

217 facility where the intervention was provided (land, buildings etc.). Sources of data for these variables

218 included public health system financial records and project's financial records. All costs were cal-

219 culated in Pakistani rupees (PKR) and are reported in Pakistani Rupees and United States Dollars for

21

the year 2016, when the study was implemented ([1]Exchange rate 1 USD= PKR 104). No adjustment was made for Purchasing Power Parity (PPP) since the focus of interest was on the actual resource costs incurred in the study country (rather than a comparison to other countries, whereby differences in the relative price of goods and services would need to be taken into account).

Statistical Analysis

The mean and standard deviation for the total cost was calculated using generalized linear regression model with Gamma distribution after adjustment for baseline total cost. The group difference and its 95% CI was also calculated [24]. The Incremental Cost-effectiveness Ratio (ICER) was calculated as the additional costs of the intervention divided by the change in HADS-A, HADS- D, HADS Total, PHQ, and WHODAS related to the intervention. The confidence intervals for ICER was estimated by non-parametric bootstrapping. The bootstrap technique sampled with replacement from the original observed paired of costs and effects, maintaining the correlation structure between costs and benefits, to create a new dataset with 1000 observations. For each bootstrap resample, an estimate of differential total mean costs, expected mean effectiveness was calculated [25]. The 95% CIs for the differential estimates were derived from the calculated 2.5th and 97.5th percentiles. We plotted cost-effectiveness acceptability curves [26] to evaluate the probability of PM+ intervention being cost-effective at increasing monetary values representing willingness-to-pay thresholds for PM+ intervention from policy makers' perspective [27]. For the effectiveness data, we used linear mixed models to study treatment effects as indicated in our main trial report [12] which allowed the number of observations to vary at random between subjects and effectively handles missing data [28].. 14% cost data was missing for medicines, complementary medicines, seeking retreats and religious help and for outpatient services at the end point. Summary stats for each specific cost were presented without imputation but the total cost were calculated assuming missing data as 0 in a conservative way [25].

Results

As reported in the clinical effectiveness evaluation [12], mean combined depression and anxiety symptom scores on HADS were significantly lower at 3-months post-intervention (AMD, −5.75; 95%

---

[1] Global Economic Data, Indicators, Charts, & Forecasts: CEIC
https://www.ceicdata.com/en

248 CI, −7.21 to −4.29). Similarly, functional impairment significantly improved (AMD, −4.17; 95% CI,

249 −5.84 to −2.51) on WHODAS-12 in the intervention arm compared to EUC arm. At baseline depression

250 rate was 94.2% and 89.4% in intervention and EUC arms respectively. at the end of 3-months follow

251 up period, the intervention arm had significantly lower rates of depression (26.9%) compared to EUC

252 arm (58.9%) (risk difference, −31.98; 95% CI: −41.03 to −22.94).

253

254

255 **Costs**

256 No significant difference in the cost of other health-care services accessed by study participants was

257 observed between treatment and control groups, with the exception of religious help and retreats. The

258 mental health condition of the majority of trial participants did not result in reduction in their or their

259 family members or friends' usual work/activities (Table 1). Table 2 presents summary statistics and

260 cost results from the mixed-model analysis.

261

262 With an international master trainer/supervisor total cost of delivering PM+ intervention per participant

263 was PKR 16,967 (US $ 163.14). Total intervention arm costs (PM+ costs plus cost of services accessed

264 by intervention arm) was PKR17,473 (SD, 912) or US$ 168. The cost of EUC (treatment as usual plus

265 cost of services accessed by control arm participant) was PKR 848 (SD, 1734) or US $ 8.15 (See Table

266 2).

267 Substituting the cost of international master trainer/supervisor with national trainer would substantially

268 decrease intervention costs. Total cost of delivering PM+ intervention, involving a national master

269 trainer/supervisor, was estimated to be PKR 3,645 (US $ 35.04). This would be PKR 729 (US $ 7.00)

270 per session. Total costs of delivering the intervention (with a national trainer/supervisor) plus EUC in

271 the intervention arm would be PKR 4151 (SD, 912) or US$ 40.

272

273 **Cost-effectiveness**

274 Incremental cost-effectiveness ratios (ICERs) indicate that the intervention was both more effective

275 and costlier than EUC for all the health outcomes studied (Table 3). Analysis was conducted to evaluate

276 the cost-effectiveness of PM+ intervention under two scenarios; 1) PM+ delivery by lay health workers

21

277   supervised by international master trainer/supervisor (as observed in the trial) and 2) PM+ delivery by

278   lay health workers supervised by local supervisor. The second scenario will be the case for scale-up of

279   the intervention package in real world setting. The additional costs associated with the intervention led

280   to a relative improvement in outcomes, e.g. the mean cost per unit score improvement in anxiety and

281   depression on HADS was PKR 2957 (95% CI: 2262, 4029) or US\$ 28 with an international

282   trainer/supervisor. This would be PKR 588 (95% CI: 434, 820) or US\$ 6 with a national

283   trainer/supervisor; with an international supervisor, each 1-point improvement on WHODAS costed

284   PKR 4097 (95% CI: 2978, 6046) or US\$ 40 and with a national supervisor it was estimated to be PKR

285   815 (95% CI: 576, 1225) or US\$ 8. We plotted 1,000 resampled estimates of costs and outcomes on a

286   cost-effectiveness plane for the primary and secondary outcomes. The results show that all the

287   resampled estimates fall in the upper-right quadrant, i.e. PM+ intervention is 'more effective but

288   costlier' in all of the resampled estimates.

289   The mean ICER to successfully treat a case of depression (PHQ-9 cut-off 10 or above) using an

290   international supervisor was PKR 53,770 (95% CI: 39,394, 77,399) [US\$ 517] versus a local supervisor

291   PKR 10,705 (95% CI: 7731, 15,627) [US\$ 102.93]. ICERs for other outcome measures are compared

292   in Table 3.

293   The cost-effectiveness acceptability curves of PM+ intervention on the outcomes of HADS (anxiety &

294   depression) and WHODAS-12 with an international specialist supervisor are provided in Figures 1a

295   and 2a. The intervention has more than 90% probability of being cost-effective as compared to EUC

296   above a willingness-to-pay threshold of PKR 7000 (US\$ 67) for a one-point improvement in depression

297   and anxiety (HADS Total) (Figure 1a) and PKR 6000 (US\$ 57) for a one-point improvement in

298   functioning (WHODAS) using international supervisors (Figure 2a). These thresholds would be

299   reduced by 80% using local supervisors (Figure 1b & 2b).

300   **Discussion**

301   Our results show that PM+ intervention is more effective and more costly than EUC in reducing

302   symptoms of anxiety and depression. Although there is inevitable uncertainty around point estimates,

303   our analysis has shown that even at very modest levels of willingness to pay for a one-point

304   improvement in symptoms or functioning outcomes there is at least a 90% probability of this

21

intervention being a cost-effective use of resources compared to enhanced usual care. We concluded that the value is 'modest' because that amount is equivalent to, for example, less than 10% of the minimum monthly wage in Pakistan in 2017 [29]. These findings are consistent with evidence from LMICs on the cost-effectiveness of task-shifting approach to deliver psychological interventions compared with EUC delivered by primary health care physicians, for the treatment of common mental disorders [30, 31]. With the current model of training and supervision from international master trainer/supervisor, the intervention was 5 times more costly for treating one person with depression, compared to modelled costs of training and supervision from local trainers. This emphasizes the need for building the capacity for local mental health workforce [32].

The resources, capacity and infrastructure for mental health services research including health economic evaluation alongside randomized controlled trials is limited in humanitarian settings of LMICs [33]. This is one of the very few studies to evaluate the cost-effectiveness of a psychological intervention in a humanitarian setting. There are only a few published studies on the cost-effectiveness of task-shifting interventions in global mental health. Araya et al (2006) evaluated the incremental cost-effectiveness of a stepped-care multicomponent program for the treatment of depressed women in primary care in Chile. The stepped-care program was more effective and costlier than usual care (an extra US$ 0.75 per depression-free day) [34]. Buttorff et al (2012) conducted an economic evaluation of a task-shifting intervention for the treatment of depressive and anxiety disorders in primary-care settings in India. They concluded that the use of lay heath workers for treatment of CMDs in the public primary-care facilities was not only cost-effective but also cost-saving. The mean health system cost per case recovered at the end of follow-up was US$ 128 (95% CI: 105 to 157) in the intervention arm and US$ 149 (95% CI: 131 to 169) in the control arm [30]. Other similar studies of lay-health counsellor delivered psychological interventions from India [31] have replicated the findings of cost-effectiveness of task-shifting interventions for treating depression and alcohol problems in primary care settings. Sikandar et al., (2019) evaluated the cost-effectiveness of a peer-volunteer delivered CBT based intervention for post-natal depression versus EUC in community settings of rural Pakistan. The intervention was costlier as compared to EUC but was effective in improving the severity of post-natal depression (costs per unit improvement in PHQ-9 score of US $15·50 (9·59 to 21·61) for the whole study period. The intervention had a 98% probability of being cost-effective over a willingness-to-pay

21

334   threshold of US$ 60 per unit of improvement on PHQ-9 score compared to EUC [35]. Although it is

335   difficult to compare the results of cost-effectiveness evaluations across studies due to differences in

336   analytical approaches, treatment conditions and different outcome measures, the results of these studies

337   demonstrate cost-effectiveness of brief psychological intervention using a task-shifting approach.

338   During humanitarian crises, health systems tend to be overwhelmed, human resources are overstretched

339   and access to specialists for referral and support is limited. It is therefore, important to determine how

340   interventions with proven efficacy can be scaled-up in a cost effective way [36]. Our study and evidence

341   from the literature supports the effectiveness of implementation strategies such as task-shifting and

342   trans-diagnostic approaches to bridge the treatment gap for mental health problems in low resource

343   settings. With the increased availability of evidence-based psychological intervention packages, further

344   health economic evaluations are needed to inform the resource needs to scale-up evidence-based care

345   for mental health.

346   **Limitations**

347   A limitation of the cost-effectiveness approach used in our study is that the results are limited to direct

348   health care costs and health-related outcomes of PM+ intervention, and does not extend to the wider

349   economic or social value of investing in mental health, which may be quite significant in a humanitarian

350   context. The future health economic evaluations in global mental health will benefit by integrating the

351   opportunity and time cost of lay health workers and non-specialists. The added value that results from

352   such task-sharing implementation strategies in terms of empowerment, opportunities and career growth

353   for non-specialist health work force as well as increase in treatment coverage for priority mental health

354   conditions will also need to be accounted for in future studies. We did not make any adjustment for

355   purchasing power parity since the focus of this study was on the actual resource costs incurred in the

356   study country. However, for the purpose of international comparison, the PPP adjusted total

357   intervention costs of PM+ were I$ 546 per participant. Estimated costs of delivering PM+ using a

358   national master trainer in Pakistan would be I$ 114 per participant. Another limitation of our study is

359   that we estimated costs per point reduction in symptoms of anxiety and depression and cost per case

360   recovered from depression which limits the ability to compare results with other interventional studies

361   on the basis of cost-utility measures (QALYs). Future studies may use change in health outcomes that

362   are easily interpretable and meaningful enough for policy makers to make decision and should also

21

363 collect data on population-based health state preference scores that would enable the calculation of

364 Quality Adjusted Life Years (QALYs).

365 **Conclusions**

366 The literature on cost effectiveness of interventions for treating common mental disorders in LMICs,

367 especially in humanitarian context is limited to only few studies. Present study provides the evidence

368 on cost-effectiveness of a task-shifting intervention using a trans-diagnostic approach. We found that

369 the intervention was effective but more costly for treating one person with depression when training

370 and supervision to lay health workers was provided by an international master trainer. We conclude

371 that PM+ may be a cost-effective intervention by using the training and supervision provided by the

372 local health workers in primary health care settings. With the increased availability of evidence-based

373 psychological intervention packages, further health economic evaluations are needed to inform the

374 resource needed to scale-up evidence-based care for mental health.

375

376

377

21

Table 1: *Health services utilization (including religious help and retreats, inpatient services and reduced usual work/activities due to health condition) across two arms at baseline and during past 3-months

		Group	Baseline			Endpoint		
			N (%)	Mean number of visits (SD)	Mean Duration in Mins (SD)	N (%)	Mean number of visits (SD)	Mean Duration in Mins (SD
Outpatient services	Traditional healer	PM+	40 (12.0)	4.03 (3.83)	26 (28.04)	9 (3.0)	3.38 (3.15)	6.54 (16.75)
		TAU	50 (15.1)	3.47 (2.50)	25.13 (25.17)	19 (6.3)	2.26 (0.80)	5.00 (9.71)
	Mental health professional	PM+	91 (29.4)	4.36 (4.73)	15.82 (13.08)	80 (26.9)	3.61 (1.87)	16.73 (9.39)
		TAU	76 (24.5)	3.09 (2.38)	17.21(15.28)	98 (33.0)	3.08 (1.49)	17.48 (9.98)
	Medical doctor	PM+	57 (18.4)	2.98 (2.20)	17.93(24.58)	39 (13.1)	2.17 (1.72)	11.79 (7.23)
		TAU	54 (17.5)	3.56 (4.23)	23.29(29.42)	37 (12.5)	1.94 (1.01)	16.67 (12.50)
	Community health worker	PM+	56 (16.9)	4.90 (5.72)	---	25 (8.2)	4.0 (2.58)	---
		TAU	54 (16.3)	3.87 (4.33)	---	25 (8.2)	2.54 (1.53)	---
	Any Others services	PM+	11 (3.4)	2.56 (2.87)	---	6 (2.0)	1.20 (0.44)	---
		TAU	8 (2.5)	1.38 (0.91)	---	3 (1.0)	2.0 (1.73)	---
Religious help and retreats		PM+	37 (11)	6.86 (11.90)	---	7 (2.4)	3.71 (5.02)	---
		TAU	45 (13.4)	3.33 (4.84)	---	14 (4.8)	3.15 (2.99)	---
Inpatient services		PM+	8 (2.3)	3.29 (2.43) *	---	7 (2.3)	7.20 (12.75) *	---
		TAU	13 (3.8)	3.91 (4.10) *	---	8 (2.6)	2.5 (0.53) *	---
Reduced usual work/activities due to health condition (oneself/family		PM+	6 (1.8)	21.33 (15.01) **	---	0 (0.0)	---	---

21

| member) | TAU | 1 (0.3) | -- | --- | 1 (0.3) | --- | --- |

 * **Night stays in hospital-** In case of inpatient services only

** Mean number of days of reduced usual work/activities due to health condition (oneself/family member)

Table 2: Cost of health services (outpatient, inpatient care, drugs and complimentary medicines and religious retreats) by trial arm in PKR (1 USD = 104 PKR; 2016)

Cost of Services	Time point	Descriptive statistics n; mean* (SD)*				Difference in LS mean (95%CI)	p-value
		Intervention (N=172)		EUC (N=174)			
		N	Mean (SD)	N	Mean (SD)		
Out-patient care	Pre-Treatment	106	2641 (14946)	95	727 (1161)		
	Follow-Up	73	485 (651)	72	667 (1033)	-182 (-465,101)	0.206
	Change since baseline	49	743(2751)	41	305(984)	437(-462,1281)	0.336
In-patient care	Pre-Treatment	170	135 (929)	172	273 (1545)		
	Follow-Up	142	49 (344)	155	171 (1056)	-122 (-304,61)	0.191
	Change since baseline	140	114(866)	153	108(1953)	6(-337,349)	0.971
Drugs/medications	Pre-Treatment	158	736 (1364)	159	725 (1232)		
	Follow-Up	132	277 (650)	149	228 (461)	50 (-82,181)	0.458
	Change since baseline	124	378(1314)	136	496(1341)	-118(-442,207)	0.477
Complimentary medicines	Pre-Treatment	168	124 (624)	167	110 (945)		
	Follow-Up	139	10 (88.14)	156	3 (40)	7 (-9,22)	0.393
	Change since baseline	136	55(456)	150	115(998)	-60(-244,123)	0.518
Religious Retreats	Pre-Treatment	167	390 (2208)	165	674 (3773)		
	Follow-Up	136	4 (43)	154	131 (655)	-127 (-238,-17)	0.024
	Change since baseline	131	432(2451)	145	626(4080)	-193(-983,596)	0.638
Total cost of all services	Pre-Treatment	172	3145 (14302)	174	2445 (6053)		
	Follow-Up	145	601 (694)	159	848 (1734)	-247 (-568,73)	0.130
	Change since baseline	145	2746 (15491)	159	1714 (6632)	1032(-1709,3774)	0.444
Total cost of intervention with international specialist supervisor[2]		172	17473 (912)	159	848 (1734)	16625 (16329,16922)	<.0001
Total cost of intervention with local specialist supervisor[3]		172	4151 (912)	159	848 (1734)	3303 (3007,3600)	<.0001

Table 2 shows costs of other services accessed by the participants. The data was collected using CSRI at baseline and 3 months' post-intervention follow-up assessment.

---

[2] Intervention costs plus cost of services. The cost of intervention with international supervisor is PKR 16,967
[3] Intervention costs plus cost of services. The cost of intervention with local supervisor is PKR 3,645

21

Table 3: Incremental Cost Effectiveness Ratios (ICERs) for PM+ intervention in PKR (1 USD = 104 PKR; 2016)

Endpoint	International specialist supervisor		Local specialist supervisor	
	Mean ICER	95% CI	Mean ICER	95% CI
HADS Anxiety	6172.99	[4575.49,8787.73]	1228.91	[882.86,1796.12]
HADS Depression	5704.27	[4384.51, 7651.85]	1135.81	[849.23,1561.68]
HADS Total	2957.45	[2261.64, 4029.00]	588.82	[434.01,820.27]
WHO DAS	4096.51	[2978.13, 6045.66]	815.89	[575.80,1225.10]
Depression caseness	53769.91	[39393.57, 77398.62]	10705.35	[7730.95,15627]

Note: (1) The cost was estimated after adjusting several baseline variables (baseline total cost, age, gender, occupation, marital status). (2) We used non-parametric bootstrapping to estimate confidence intervals with1000 resamples.

Abbreviations.; HADS = Hospital Anxiety and Depression Scales (subscale score range: 0-21; higher scores indicate elevated anxiety or depression, respectively); WHODAS = WHO Disability Assessment Schedule (total score range: 0-48; higher scores indicate more severe impairment); Depression caseness defined as (PHQ-9 cut-off 10 or above), PHQ = Patient Health Questionnaire

21

Figure 1a: Cost-effectiveness acceptability curve for PM+ with international supervisor (in PKR) (1 USD = 104 PKR; 2016)

Figure 1b: Cost-effectiveness acceptability curve for PM+ - with local trainer (in PKR) (1 USD = 104 PKR; 2016)

Figure 2a: Cost-effectiveness acceptability curve for PM+ with international supervisor (in PKR) (1 USD = 104 PKR; 2016)

WHO DAS

Figure 2b: Cost-effectiveness acceptability curve for PM+ with local supervisor (in PKR) (1 USD = 104 PKR; 2016)

21

References:

1. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine J, Angermeyer MC, Bernert S, Morosini P, Polidori G: **Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys**. *JAMA* 2004, **291**(21):2581-2590.

2. Saxena S, Thornicroft G, Knapp M, Whiteford H: **Resources for mental health: scarcity, inequity, and inefficiency**. *The Lancet* 2007, **370**(9590):878-889.

3. Thornicroft G: **Most people with mental illness are not treated**. *The Lancet* 2007, **370**(9590):807-808.

4. **Global Humanitarian Overview. Geneva, Switzerland: United Nations Office for the Coordination of Humanitarian Affairs** [https://interactive.unocha.org/publication/globalhumanitarianoverview/]

5. Steel Z, Chey T, Silove D, Marnane C, Bryant RA, Van Ommeren M: **Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement: a systematic review and meta-analysis**. *JAMA* 2009, **302**(5):537-549.

6. Roberts B, Browne J: **A systematic review of factors influencing the psychological health of conflict-affected populations in low-and middle-income countries**. *Global public health* 2011, **6**(8):814-829.

7. Tol WA, Barbui C, Van Ommeren M: **Management of acute stress, PTSD, and bereavement: WHO recommendations**. *JAMA* 2013, **310**(5):477-478.

8. Bangpan M, Lambert F, Chiumento A, Dickson K: **The impact of mental health and psychosocial support programmes for populations affected by humanitarian emergencies: a systematic review protocol**. 2016.

9. Allden K, Jones L, Weissbecker I, Wessells M, Bolton P, Betancourt T, Hijazi Z, Galappatti A, Yamout R, Patel P: **Mental health and psychosocial support in crisis and conflict: report of the Mental Health Working Group**. *Prehospital and Disaster Medicine* 2009, **24**(S2):s217-s227.

10. Rahman A, Riaz N, Dawson KS, Usman Hamdani S, Chiumento A, Sijbrandij M, Minhas F, Bryant RA, Saeed K, van Ommeren M: **Problem Management Plus (PM+): pilot trial of a WHO transdiagnostic psychological intervention in conflict-affected Pakistan**. *World Psychiatry* 2016, **15**(2):182-183.

11. Sijbrandij M, Farooq S, Bryant RA, Dawson K, Hamdani SU, Chiumento A, Minhas F, Saeed K, Rahman A, Ommeren M: **Problem Management Plus (PM+) for common mental disorders in a humanitarian setting in Pakistan; study protocol for a randomised controlled trial (RCT)**. *BMC psychiatry* 2015, **15**(1):232.

12. Rahman A, Hamdani SU, Awan NR, Bryant RA, Dawson KS, Khan MF, Azeemi MM-U-H, Akhtar P, Nazir H, Chiumento A: **Effect of a multicomponent behavioral intervention in adults impaired by psychological distress in a conflict-affected area of Pakistan: a randomized clinical trial**. *JAMA* 2016, **316**(24):2609-2617.

13. Minhas F, Mubbashar M: **Validation of General Health Questionnaire (GHQ-12) in primary care settings of Pakistan**. *J Coll Physicians Surg Pak* 1996, **6**:133-136.

14. WHO: **Section 8 Syntax for automatic computation of overall score using SPSS: Measuring health and disability-Manual for WHO disability assessment schedule WHODAS 2.0**: World Health Organization; 2010.

21

15.   Dawson KS, Bryant RA, Harper M, Kuowei Tay A, Rahman A, Schafer A, van Ommeren M: **Problem Management Plus (PM+): A WHO transdiagnostic psychological intervention for common mental health problems**. *World Psychiatry* 2015, **14**(3):354-357.

16.   McEvoy PM, Nathan P, Norton PJ: **Efficacy of transdiagnostic treatments: A review of published outcome studies and future research directions**. *Journal of Cognitibe Psychology* 2009, **23**(1):20-33.

17.   World Health Organization: **Problem Management Plus (PM+): Individual Psychological Help for Adults Impaired by Distress in Communities Exposed to Adversity (Generic Field-Trial Version 1.0).** In*. Geneva, Switzerland:World Health Organization; 2016.

18.   Zigmond AS, Snaith RP: **The hospital anxiety and depression scale**. *Acta Psychiatrica Scandinavica* 1983, **67**(6):361-370.

19.   Mumford D, Tareen I, Bajwa M, Bhatti M, Karim R: **The translation and evaluation of an Urdu version of the Hospital Anxiety and Depression Scale**. *Acta Psychiatrica Scandinavica* 1991, **83**(2):81-85.

20.   Kroenke K, Spitzer RL, Williams JB: **The PHQ-9: validity of a brief depression severity measure**. *Journal of general internal medicine* 2001, **16**(9):606-613.

21.   **The PTSD Checklist for DSM-5 (PCL-5)** [http://www.ptsd.va.gov/professional/assessment/adult-sr/ptsd-checklist.asp.]

22.   Chisholm D, Knapp MRJ, Knudsen HC, Amaddeo F, Gaite L, Van Wijngaarden B, Group ES: **Client socio-demographic and service receipt inventory–European version: development of an instrument for international research: EPSILON Study 5**. *British Journal of Psychiatry* 2000, **177**(S39):s28-s33.

23.   Patel V, Weiss HA, Chowdhary N, Naik S, Pednekar S, Chatterjee S, De Silva MJ, Bhat B, Araya R, King M: **Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial**. *The Lancet* 2010, **376**(9758):2086-2095.

24.   Mccrone P, Knapp M, Proudfoot J, Ryden C, Cavanagh K, Shapiro DA, Ilson S, Gray JA, Goldberg D, Mann AJTBJoP: **Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial**. *European Journal of Psychotraumatology* 2004, **185**(1):55-62.

25.   Khan I: **Design & Analysis of clinical trials for Economic Evaluation & Reimbursement: an applied approach using SAS & STATA**: Chapman and Hall/CRC; 2015.

26.   Baltussen RM, Hutubessy RC, Evans DB, Murray CJJIjotaihc: **Uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables**. *International Journal of technology Assessment in Health Care* 2002, **18**(1):112-119.

27.   Fenwick E, Marshall DA, Levy AR, Nichol GJBhsr: **Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation**. *BMC Health Services Research* 2006, **6**(1):52.

28.   Little RJ, Rubin DB: **Statistical analysis with missing data**, vol. 793: John Wiley & Sons; 2019.

29.   Govt. of Pakistan Finance Division Islamabad: **Federal Budget** In*.; 2017.

30.   Buttorff C, Hock RS, Weiss HA, Naik S, Araya R, Kirkwood BR, Chisholm D, Patel V: **Economic evaluation of a task-shifting intervention for common mental disorders in India**. *Bulletin of the World Health Organization* 2012, **90**(11):813-821.

31.   Weobong B, Weiss HA, McDaid D, Singla DR, Hollon SD, Nadkarni A, Park A-L, Bhat B, Katti B, Anand A *et al*: **Sustained effectiveness and cost-effectiveness of the Healthy Activity Programme, a brief psychological treatment for depression delivered by lay counsellors in primary care: 12-month follow-up of a randomised controlled trial**. *Plos Medicine* 2017, **14**(9):e1002385.

21

32. Murray LK, Dorsey S, Bolton P, Jordans MJ, Rahman A, Bass J, Verdeli H: **Building capacity in mental health interventions in low resource countries: an apprenticeship model for training local providers**. *International Journal of Mental Health Systems* 2011, **5**(1):30.

33. Chisholm LCa: **Cost-Effectiveness and Affordability of Interventions, Policies, and Platforms for the Prevention and Treatment of Mental, Neurological, and Substance Use Disorders, In, Mental, Neurological, and Substance Use Disorders**, vol. 4, 3 edn. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2016.

34. Araya R, Flynn T, Rojas G, Fritsch R, Simon G: **Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile**. *American journal of psychiatry* 2006, **163**(8):1379-1387.

35. Sikander S, Ahmad I, Atif N, Zaidi A, Vanobberghen F, Weiss HA, Nisar A, Tabana H, Ain QU, Bibi A *et al*: **Delivering the Thinking Healthy Programme for perinatal depression through volunteer peers: a cluster randomised controlled trial in Pakistan**. *Lancet Psychiatry* 2019, **6**(2):128-139.

36. Ventevogel P, van Ommeren M, Schilperoord M, Saxena S: **Democratic Republic of the Congo»**. *J Bulletin of the World Health Organization* 2015, **93**:666-666A.

21

1   **Cost-effectiveness of WHO Problem Management Plus for adults impaired by psychological**
2   **distress in a post-conflict setting of Pakistan**

3

4   Syed Usman Hamdani, Ph.D., University of Liverpool, UK & Human Development Research

5   Foundation, Islamabad, Pakistan

6   Zill-e-Huma, MPH, Human Development Research Foundation, Islamabad, Pakistan

7   Atif Rahman, Ph.D., University of Liverpool, Liverpool, UK

8   Duolao Wang, PhD, Liverpool School of Tropical Medicine, UK

9   Tao Chen, PhD, Liverpool School of Tropical Medicine, UK

10   Mark van Ommeren, Ph.D., Department of Mental Health and Substance Abuse, World Health

11   Organization, Geneva, Switzerland

12   Dan Chisholm, Ph.D., WHO Regional Office for Europe; Copenhagen, Denmark

13   Saeed Farooq, Ph.D., Lady Reading Hospital, Peshawar, Pakistan and Research Institute for Primary

14   Care & Health Sciences, Keele University, UK

15   **Corresponding Author:**
16   Syed Usman Hamdani
17   Human Development Research Foundation,
18   House No# 6, street 55, F-7/4 Islamabad,
19   44000 Pakistan.
20   E: s.u.hamdani@liverpool.ac.uk
21

22   **Word count (except abstract): 3497~~3224~~**

23

24

25

26

27

1

Author contribution:

Hamdani, Zill-e-Huma, Chen and Wang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Hamdani, Rahman, Farooq, Chisholm, van Ommeren.

Acquisition, analysis, or interpretation of data: Hamdani, Zill-e-Huma, Wang, Farooq, van Ommeren, Chisholm

Drafting of the manuscript: Hamdani, Zill-e-Huma, Rahman, van Ommeren, Chisholm, Farooq

Critical revision of the manuscript for important intellectual content: Hamdani, Zill-e-Huma, Rahman, Farooq, Chisholm, Chen, Wang, van Ommeren.

Statistical analysis: Hamdani, Zill-e-Huma, Chisholm, Chen, Wang

Obtained funding: van Ommeren, Rahman, Hamdani.

Administrative, technical, or material support: Hamdani, Zill-e-Huma, Rahman, Farooq, van Ommeren.

Study supervision: Hamdani, Rahman, Farooq, van Ommeren.

Disclaimer

2

61   **Competing interests**

63

64

ABSTRACT

Background

With the development of evidence-based interventions for treatment of priority mental health conditions in humanitarian settings, it is important to establish the cost-effectiveness of such interventions to enable their scale-up.

Aims

To evaluate the cost-effectiveness of Problem Management Plus (PM+) intervention, compared to Enhanced Usual Care (EUC) for common mental disorders in primary healthcare in Peshawar, Pakistan.

Methods

We randomly allocated 346 participants to either PM+ (n=172) or EUC (n=174). Effectiveness was measured using Hospital Anxiety and Depression Scale (HADS) at 3 months' post-intervention. Cost-effectiveness analysis was performed as incremental costs (measured in Pakistani Rupees [PKR] per unit change in anxiety, depression and functioning scores.

Results

The total cost of delivering PM+ per participant was estimated at PKR 16,967 (US $ 163.14) using an international master trainer and supervisor, and PKR 3,645 (US$35.04; US$ 7 per session) employing a national trainer. The mean cost per unit score improvement in anxiety and depression symptoms on HADS was PKR 2957 (95% CI: 2262, 4029) [US$ 28] with international trainer/supervision and PKR 588 (95% CI: 434, 820) or US$ 6 with local trainer/supervisor. The mean Incremental Cost-Effectiveness Ratio (ICER) to successfully treat a case of depression (PHQ-9 $\geq$ 10) using an international supervisor was PKR 53,770 (95% CI: 39,394, 77,399) [US$ 517] versus a local supervisor PKR 10,705 (95% CI: 7731, 15,627) [US$ 102.93].

Conclusions

The PM+ was more effective but also more costly than EUC in reducing symptoms of anxiety, depression and improving functioning in adults impaired by psychological distress in a post-conflict setting of Pakistan.

Key words: Cost-effectiveness, lay health workers, Low and Middle Income Countries (LMIC), humanitarian settings, Problem Management Plus, Common Mental Disorders (CMDs)

Trial Registration anzctr.org.au Identifier: ACTRN12614001235695

4

103   Mental health problems cause a significant burden of disease in Low and Middle Income Countries

104   (LMICs), yet the documented 'mental health treatment gap' is up to 90% [1-3]. The need for mental

105   health services is much greater in populations affected by humanitarian crises. More than 135 million

106   people are in need of humanitarian assistance due to ongoing humanitarian crises and conflicts globally

107   [4]. A systematic review and meta-analysis of mental health outcomes in population affected by conflict

108   and displacements showed that mood and anxiety disorders were common, with rates of 17.3% for

109   depression and 15.4% for posttraumatic stress disorder [5]. Epidemiological studies from areas affected

110   by humanitarian crises in Pakistan found high rates of psychological distress in these populations. One

111   study reported rates as high as 38% to 65% for psychological distress in women [6, 7]. Majority of

112   people have no access to mental health services in such settings [6]. Over the past decade, significant

113   progress has been made in terms of availability of evidence based mental health intervention packages

114   for populations affected by humanitarian crises [8]. However, sustainability and scalability of such

115   psychological interventions remains a challenge in populations affected by humanitarian crises in low

116   resource settings globally [9].

117   We developed and tested a brief, multicomponent behavioural intervention, Problem Management Plus

118   (PM+) delivered by lay health workers for Common Mental Disorders (CMDs) in conflict affected

119   settings. The intervention was effective for treating the symptoms of CMDs in a post-conflict setting

120   of Pakistan. Trial protocol and results of pilot and definitive clinical trials have been published [10-12].

121   In the present study, we conduct an economic evaluation alongside the randomized controlled trial to

122   assess the cost-effectiveness of this intervention in order to inform policy and implementation in routine

123   clinical practice.

124   **Method**

125   **Study site and participants**

126   Participants included 346 primary care attendees with high level of psychological distress (score above

127   2 on General Health Questionnaire [GHQ-12]) [13] and functional impairment (score above 16 on

128   World Health Organization Disability Assessment Schedule 2.0 [WHODAS 2.0]) [14]. The participants

129   were individually randomized in 1:1 ratio to either intervention arm i.e. PM+ (n=172) along with

130   Enhanced Usual Care (EUC)) or the Control arm consisting of Enhanced Usual Care (EUC) only

131   (n=174). The study was approved locally by the Institutional Review and Ethics Board of the

132 Postgraduate Medical Institute, Lady Reading Hospital, Peshawar, and by the WHO Ethical Review

133 Committee. Written informed consent was obtained from all study participants.

The Intervention

135 Participants in the intervention arm received a brief multicomponent intervention called Problem

136 Management Plus (PM+) [15]. The intervention is trans-diagnostic as it applies the same underlying

137 principles across mental disorders, without tailoring the protocol to specific diagnoses [16]. PM+ is

138 based on well-established principles of problem solving and behavioural techniques. It is designed to

139 be used for adults experiencing common mental health problems (e.g. anxiety, stress, depression and

140 grief) only. It is not suitable for the treatment of severe mental health problems (including psychosis or

141 risk for suicide). Both an individual and group version of the intervention exists. The current study

142 involves the individual version.

143 PM+ consists of 5 weekly face-to-face sessions of 90 minutes each, delivered by trained lay health

144 workers. The intervention is composed of four core strategies i.e. stress management, managing

145 problems, get going, keep doing (behavioural activation), strengthening social support, introduced

146 sequentially in the intervention sessions. In the last session, all the strategies are reviewed with a

147 particular emphasis on using these strategies for self-management in the future and to prevent relapse.

148

149 Training and supervision followed a cascade model. An international master trainer trained local

150 trainers in a 6-day training workshop. Training consisted of intervention delivery, training and

151 supervision skills. Local trainers cascaded the training to lay health workers (with 12-16 year of

152 education) in an 8-day training. Lay health workers were provided weekly supervision by local

153 trainers/supervisors (hereafter local supervisor) who were in turn, supervised monthly by the

154 international master trainer/supervisor (hereafter international supervisor) via video conference for 2

155 to 3 hours. The intervention is available in Urdu and English on the WHO website [17]. Further details

156 of intervention are described elsewhere [15].

Enhanced care as usual

158 The participants in both intervention arm and control arm received Enhanced Usual Care (EUC). The

159 treatment was enhanced as the Primary Health Care (PHC) physicians in the participating primary

160 health care centres received a 5-day training in the management of Common Mental Disorders (CMDs)

6

161 in primary health care settings. The training was reinforced through a one-day refresher training for the

162 primary health care physicians. The study participants in both arms were able to seek other health care

163 services from their PHC physicians.

164 **Data Collection**

165   **A. Health outcomes**

166 The outcomes were measured at baseline and 3 months' post-intervention. The cost-effectiveness

167 analysis was performed as incremental costs per unit change in anxiety, depression and functioning

168 scores. The primary outcome was change in symptoms of anxiety and depression measured with the

169 Hospital Anxiety and Depression Scale (HADS) [18, 19]. Severity of symptoms was measured using

170 the -HADS-Anxiety (anxiety; 7 items; possible score range, 0-21) and Depression (depression; 7 items;

171 possible score range, 0-21). Higher scores indicate more anxiety and/or depression. Secondary

172 outcomes were functional impairment and presence of depressive disorders. WHODAS-12 was used

173 to assess functional impairment. Polytomous scoring algorithm of WHODAS-12 was used to transform

174 the functional impairment scores on a scale of 1-100[14]. Presence of depressive disorder was measured

175 using a 9-item Patient Health Questionnaire (PHQ-9) [20]. Other secondary outcome measure included

176 PCL-5 [21], results of which are attached as a web appendix.

177

178 **B. Health resource use profiling**

179 The data on health resource use was collected using the Client Services Receipt Inventory (CSRI)

180 [22], which records the clients' contact with out-patient services (i.e. mental health specialist, general

181 physician, traditional healer, community health workers etc.), inpatient (hospital admissions) services

182 and out of pocket costs associated with travel, medications and tests/investigations during the preceding

183 recall period. A section on seeking religious help and retreats was added to adapt the tool for use in

184 local population. Study participants self-reported their health-care utilization, medication use and out-

185 of-pocket expenditures on CSRI [22] at baseline and 3-months' post-intervention.

186

187 **C. Cost measurement and analysis**

188 Economic analysis was conducted primarily from a health system perspective, consisting of a) costs

189 incurred over the trial period in the delivery of the intervention itself, b) use of other healthcare and

7

190 related services by study participants, including religious help and retreats, and c) patient and family

191 costs (such as number of days with reduced working hours, informal caregiving time by relatives or

192 friends as well as travel costs and time spent travelling to or waiting for consultations). No discounting

193 of costs was applied since the study was performed within one year.

194

195 *Intervention costs:* These included costs for the intervention adaptation workshops, translations of

196 intervention manual and training materials; printing of adapted training manuals, staff recruitment,

197 training and supervision. Supervision costs included time spent by master trainer, supervisors, transport

198 costs for fieldwork supervision, and costs of all other resources used.

199

200 To estimate the cost of intervention delivery, we evaluated unit cost per minute of health care providers'

201 time including the international master trainer/supervisor, local supervisors, lay health workers and

202 physicians. The unit cost per minute was multiplied with the total estimated time spent by each health

203 care provider to the participants to calculate the total cost of intervention delivery. We calculated the

204 cost of intervention delivery with the international master trainer/supervisor and modelled the cost for

205 a local supervisor as a potentially more sustainable way to support task-shifting in low resource settings.

206 Costs of the intervention were calculated by multiplying the total contact time (number of minutes) a

207 participant had in the intervention arm with a lay health worker by the per-minute cost of the lay health

208 workers' time and the costs spent on travelling by lay health workers (unit cost calculations are

209 provided as web appendix).

210

211 Calculation of these intervention costs as well as contacts with a range of formal health care providers

212 was facilitated by the use of a simplified costing template for unit cost calculations reported in health

213 economic evaluation of mental health services [23]. Unit cost templates accounted for the costs of

214 salaries of staff employed in the provision of intervention delivery (including master trainer,

215 supervisors, lay health workers and PHC staff), facility operating costs where the service was provided,

216 overhead costs relating to the provision of service (personnel, finance etc.) and the capital costs of the

217 facility where the intervention was provided (land, buildings etc.). Sources of data for these variables

218 included public health system financial records and project's financial records. All costs were cal-

219 culated in Pakistani rupees (PKR) and are reported in Pakistani Rupees and United States Dollars for

8

220   the year 2016, when the study was implemented ([1]Exchange rate 1 USD= PKR 104). No adjustment

221   was made for Purchasing Power Parity (PPP) since the focus of interest was on the actual resource costs

222   incurred in the study country (rather than a comparison to other countries, whereby differences in the

223   relative price of goods and services would need to be taken into account).

224

225   **Statistical Analysis**

226   The mean and standard deviation for the total cost was calculated using generalized linear regression

227   model with Gamma distribution after adjustment for baseline total cost. The group difference and its

228   95% CI was also calculated [24]. The Incremental Cost-effectiveness Ratio (ICER) was calculated as

229   the additional costs of the intervention divided by the change in HADS-A, HADS- D, HADS Total,

230   PHQ, and WHODAS related to the intervention. The confidence intervals for ICER was estimated by

231   non-parametric bootstrapping. The bootstrap technique sampled with replacement from the original

232   observed paired of costs and effects, maintaining the correlation structure between costs and benefits,

233   to create a new dataset with 1000 observations. For each bootstrap resample, an estimate of differential

234   total mean costs, expected mean effectiveness was calculated [25]. The 95% CIs for the differential

235   estimates were derived from the calculated 2.5th and 97.5th percentiles. We plotted cost-effectiveness

236   acceptability curves [26] to evaluate the probability of PM+ intervention being cost-effective at

237   increasing monetary values representing willingness-to-pay thresholds for PM+ intervention from

238   policy makers' perspective [27]. For the effectiveness data, we used linear mixed models to study

239   treatment effects as indicated in our main trial report [12] which allowed the number of observations

240   to vary at random between subjects and effectively handles missing data [28] the post hoc sensitivity

241   analysis using multiple imputation was performed to assess the robustness of treatment effect to the

242   missing values. 14% cost data was missing for medicines, complementary medicines, seeking retreats

243   and religious help and for outpatient services at the end point. Summary stats for each specific cost

244   were presented without imputation but the total cost were calculated assuming missing data as 0 in a

245   conservative way [25].

246

247   **Results**

---

[1] Global Economic Data, Indicators, Charts, & Forecasts: CEIC
https://www.ceicdata.com/en

248 As reported in the clinical effectiveness evaluation [12], mean combined depression and anxiety

249 symptom scores on HADS were significantly lower at 3-months post-intervention (AMD, −5.75; 95%

250 CI, −7.21 to −4.29). Similarly, functional impairment significantly improved (AMD, −4.17; 95% CI,

251 −5.84 to −2.51) on WHODAS-12 in the intervention arm compared to EUC arm. At baseline depression

252 rate was 94.2% and 89.4% in intervention and EUC arms respectively. at the end of 3-months follow

253 up period, the intervention arm had significantly lower rates of depression (26.9%) compared to EUC

254 arm (58.9%) (risk difference, −31.98; 95% CI: −41.03 to −22.94).

255

256

257 **Costs**

258 No significant difference in the cost of other health-care services accessed by study participants was

259 observed between treatment and control groups, with the exception of religious help and retreats. The

260 mental health condition of the majority of trial participants did not result in reduction in their or their

261 family members or friends' usual work/activities (Table 1). Table 2 presents summary statistics and

262 cost results from the mixed-model analysis.

263

264 With an international master trainer/supervisor total cost of delivering PM+ intervention per participant

265 was PKR 16,967 (US $ 163.14). Total intervention arm costs (PM+ costs plus cost of services accessed

266 by intervention arm) was PKR17,473 (SD, 912) or US$ 168. The cost of EUC (treatment as usual plus

267 cost of services accessed by control arm participant) was PKR 848 (SD, 1734) or US $ 8.15 (See Table

268 2).

269 Substituting the cost of international master trainer/supervisor with national trainer would substantially

270 decrease intervention costs. Total cost of delivering PM+ intervention, involving a national master

271 trainer/supervisor, was estimated to be PKR 3,645 (US $ 35.04). This would be PKR 729 (US $ 7.00)

272 per session. Total costs of delivering the intervention (with a national trainer/supervisor) plus EUC in

273 the intervention arm would be PKR 4151 (SD, 912) or US$ 40.

274

275 **Cost-effectiveness**

276   Incremental cost-effectiveness ratios (ICERs) indicate that the intervention was both more effective

277   and costlier than EUC for all the health outcomes studied (Table 3). Analysis was conducted to evaluate

278   the cost-effectiveness of PM+ intervention under two scenarios; 1) PM+ delivery by lay health workers

279   supervised by international master trainer/supervisor (as observed in the trial) and 2) PM+ delivery by

280   lay health workers supervised by local supervisor. The second scenario will be the case for scale-up of

281   the intervention package in real world setting. The additional costs associated with the intervention led

282   to a relative improvement in outcomes, e.g. the mean cost per unit score improvement in anxiety and

283   depression on HADS was PKR 2957 (95% CI: 2262, 4029) or US$ 28 with an international

284   trainer/supervisor. This would be PKR 588 (95% CI: 434, 820) or US$ 6 with a national

285   trainer/supervisor; with an international supervisor, each 1-point improvement on WHODAS costed

286   PKR 4097 (95% CI: 2978, 6046) or US$ 40 and with a national supervisor it was estimated to be PKR

287   815 (95% CI: 576, 1225) or US$ 8. We plotted 1,000 resampled estimates of costs and outcomes on a

288   cost-effectiveness plane for the primary and secondary outcomes. The results show that all the

289   resampled estimates fall in the upper-right quadrant, i.e. PM+ intervention is 'more effective but

290   costlier' in all of the resampled estimates.

291   The mean ICER to successfully treat a case of depression (PHQ-9 cut-off 10 or above) using an

292   international supervisor was PKR 53,770 (95% CI: 39,394, 77,399) [US$ 517] versus a local supervisor

293   PKR 10,705 (95% CI: 7731, 15,627) [US$ 102.93]. ICERs for other outcome measures are compared

294   in Table 3.

295   The cost-effectiveness acceptability curves of PM+ intervention on the outcomes of HADS (anxiety &

296   depression) and WHODAS-12 with an international specialist supervisor are provided in Figures 1a

297   and 2a. The intervention has more than 90% probability of being cost-effective as compared to EUC

298   above a willingness-to-pay threshold of PKR 7000 (US$ 67) for a one-point improvement in depression

299   and anxiety (HADS Total) (Figure 1a) and PKR 6000 (US$ 57) for a one-point improvement in

300   functioning (WHODAS) using international supervisors (Figure 2a). These thresholds would be

301   reduced by 80% using local supervisors (Figure 1b & 2b).

302   **Discussion**

303 Our results show that PM+ intervention is more effective and more costly than EUC in reducing

304 symptoms of anxiety and depression. Although there is inevitable uncertainty around point estimates,

305 our analysis has shown that even at very modest levels of willingness to pay for a one-point

306 improvement in symptoms or functioning outcomes there is at least a 90% probability of this

307 intervention being a cost-effective use of resources compared to enhanced usual care. We concluded

308 that the value is 'modest' because that amount is equivalent to, for example, less than 10% of the

309 minimum monthly wage in Pakistan in 2017 [29]. These findings are consistent with evidence from

310 LMICs on the cost-effectiveness of task-shifting approach to deliver psychological interventions

311 compared with EUC delivered by primary health care physicians, for the treatment of common mental

312 disorders [30, 31]. With the current model of training and supervision from international master

313 trainer/supervisor, the intervention was 5 times more costly for treating one person with depression,

314 compared to modelled costs of training and supervision from local trainers. This emphasizes the need

315 for building the capacity for local mental health workforce [32].

316 The resources, capacity and infrastructure for mental health services research including health

317 economic evaluation alongside randomized controlled trials is limited in humanitarian settings of

318 LMICs [33]. This is one of the very few studies to evaluate the cost-effectiveness of a psychological

319 intervention in a humanitarian setting. There are only a few published studies on the cost-effectiveness

320 of task-shifting interventions in global mental health. Araya et al (2006) evaluated the incremental cost-

321 effectiveness of a stepped-care multicomponent program for the treatment of depressed women in

322 primary care in Chile. The stepped-care program was more effective and costlier than usual care (an

323 extra US$ 0.75 per depression-free day) [34]. Buttorff et al (2012) conducted an economic evaluation

324 of a task-shifting intervention for the treatment of depressive and anxiety disorders in primary-care

325 settings in India. They concluded that the use of lay heath workers for treatment of CMDs in the public

326 primary-care facilities was not only cost-effective but also cost-saving. The mean health system cost

327 per case recovered at the end of follow-up was US$ 128 (95% CI: 105 to 157) in the intervention arm

328 and US$ 149 (95% CI: 131 to 169) in the control arm [30]. Other similar studies of lay-health counsellor

329 delivered psychological interventions from India [31] have replicated the findings of cost-effectiveness

330 of task-shifting interventions for treating depression and alcohol problems in primary care settings.

331 Sikandar et al., (2019) evaluated the cost-effectiveness of a peer-volunteer delivered CBT based

12

332 intervention for post-natal depression versus EUC in community settings of rural Pakistan. The

333 intervention was costlier as compared to EUC but was effective in improving the severity of post-natal

334 depression (costs per unit improvement in PHQ-9 score of US $15·50 (9·59 to 21·61) for the whole

335 study period. The intervention had a 98% probability of being cost-effective over a willingness-to-pay

336 threshold of US$ 60 per unit of improvement on PHQ-9 score compared to EUC [35]. Although it is

337 difficult to compare the results of cost-effectiveness evaluations across studies due to differences in

338 analytical approaches, treatment conditions and different outcome measures, the results of these studies

339 demonstrate cost-effectiveness of brief psychological intervention using a task-shifting approach.

340 During humanitarian crises, health systems tend to be overwhelmed, human resources are overstretched

341 and access to specialists for referral and support is limited. It is therefore, important to determine how

342 interventions with proven efficacy can be scaled-up in a cost effective way [36]. Our study and evidence

343 from the literature supports the effectiveness of implementation strategies such as task-shifting and

344 trans-diagnostic approaches to bridge the treatment gap for mental health problems in low resource

345 settings. With the increased availability of evidence-based psychological intervention packages, further

346 health economic evaluations are needed to inform the resource needs to scale-up evidence-based care

347 for mental health.

348 **Limitations**

349 A limitation of the cost-effectiveness approach used in our study is that the results are limited to direct

350 health care costs and health-related outcomes of PM+ intervention, and does not extend to the wider

351 economic or social value of investing in mental health, which may be quite significant in a humanitarian

352 context. The future health economic evaluations in global mental health will benefit by integrating the

353 opportunity and time cost of lay health workers and non-specialists. The added value that results from

354 such task-sharing implementation strategies in terms of empowerment, opportunities and career growth

355 for non-specialist health work force as well as increase in treatment coverage for priority mental health

356 conditions will also need to be accounted for in future studies. We did not make any adjustment for

357 purchasing power parity since the focus of this study was on the actual resource costs incurred in the

358 study country. However, for the purpose of international comparison, the PPP adjusted total

359 intervention costs of PM+ were I$ 546 per participant. Estimated costs of delivering PM+ using a

360 national master trainer in Pakistan would be I$ 114 per participant. Another limitation of our study is

13

361   that we estimated costs per point reduction in symptoms of anxiety and depression and cost per case

362   recovered from depression which limits the ability to compare results with other interventional studies

363   on the basis of cost-utility measures (QALYs). Future studies may use change in health outcomes that

364   are easily interpretable and meaningful enough for policy makers to make decision and should also

365   collect data on population-based health state preference scores that would enable the calculation of

366   Quality Adjusted Life Years (QALYs).

367   **Conclusions**

368   The literature on cost effectiveness of interventions for treating common mental disorders in LMICs,

369   especially in humanitarian context is limited to only few studies. Present study provides the evidence

370   on cost-effectiveness of a task-shifting intervention using a trans-diagnostic approach. We found that

371   the intervention was effective but more costly for treating one person with depression when training

372   and supervision to lay health workers was provided by an international master trainer. We conclude

373   that PM+ may be a cost-effective intervention by using the training and supervision provided by the

374   local health workers in primary health care settings. With the increased availability of evidence-based

375   psychological intervention packages, further health economic evaluations are needed to inform the

376   resource needed to scale-up evidence-based care for mental health.

377

378

379

14

Table 1: *Health services utilization <mark>(including religious help and retreats, inpatient services and reduced usual work/activities due to health condition)</mark> across two arms at baseline and during past 3-months

			Baseline			Endpoint		
		Group	N (%)	Mean number of visits (SD)	Mean Duration in Mins (SD)	N (%)	Mean number of visits (SD)	Mean Duration in Mins (SD
Outpatient services	Traditional healer	PM+	40 (12.0)	4.03 (3.83)	26 (28.04)	9 (3.0)	3.38 (3.15)	6.54 (16.75)
		TAU	50 (15.1)	3.47 (2.50)	25.13 (25.17)	19 (6.3)	2.26 (0.80)	5.00 (9.71)
	Mental health professional	PM+	91 (29.4)	4.36 (4.73)	15.82 (13.08)	80 (26.9)	3.61 (1.87)	16.73 (9.39)
		TAU	76 (24.5)	3.09 (2.38)	17.21(15.28)	98 (33.0)	3.08 (1.49)	17.48 (9.98)
	Medical doctor	PM+	57 (18.4)	2.98 (2.20)	17.93(24.58)	39 (13.1)	2.17 (1.72)	11.79 (7.23)
		TAU	54 (17.5)	3.56 (4.23)	23.29(29.42)	37 (12.5)	1.94 (1.01)	16.67 (12.50)
	Community health worker	PM+	56 (16.9)	4.90 (5.72)	---	25 (8.2)	4.0 (2.58)	---
		TAU	54 (16.3)	3.87 (4.33)	---	25 (8.2)	2.54 (1.53)	---
	Any Others services	PM+	11 (3.4)	2.56 (2.87)	---	6 (2.0)	1.20 (0.44)	---
		TAU	8 (2.5)	1.38 (0.91)	---	3 (1.0)	2.0 (1.73)	---
Religious help and retreats		PM+	37 (11)	6.86 (11.90)	---	7 (2.4)	3.71 (5.02)	---
		TAU	45 (13.4)	3.33 (4.84)	---	14 (4.8)	3.15 (2.99)	---
Inpatient services		PM+	8 (2.3)	3.29 (2.43) *	---	7 (2.3)	7.20 (12.75) *	---
		TAU	13 (3.8)	3.91 (4.10) *	---	8 (2.6)	2.5 (0.53) *	---
Reduced usual work/activities due to health condition (oneself/family		PM+	6 (1.8)	21.33 (15.01) **	---	0 (0.0)	---	---

15

| member) | TAU | 1 (0.3) | -- | --- | 1 (0.3) | --- | --- |

 * **Night stays in hospital-** In case of inpatient services only

** Mean number of days of reduced usual work/activities due to health condition (oneself/family member)

Table 2: Cost of health services (outpatient, inpatient care, drugs and complimentary medicines and religious retreats) by trial arm in PKR (1 USD = 104 PKR; 2016)

Cost of Services	Time point	Descriptive statistics n; mean* (SD)*				Difference in LS mean (95%CI)	p-value
		Intervention (N=172)		EUC (N=174)			
		N	Mean (SD)	N	Mean (SD)		
Out-patient care	Pre-Treatment	106	2641 (14946)	95	727 (1161)		
	Follow-Up	73	485 (651)	72	667 (1033)	-182 (-465,101)	0.206
	Change since baseline	49	743(2751)	41	305(984)	437(-462,1281)	0.336
In-patient care	Pre-Treatment	170	135 (929)	172	273 (1545)		
	Follow-Up	142	49 (344)	155	171 (1056)	-122 (-304,61)	0.191
	Change since baseline	140	114(866)	153	108(1953)	6(-337,349)	0.971
Drugs/medications	Pre-Treatment	158	736 (1364)	159	725 (1232)		
	Follow-Up	132	277 (650)	149	228 (461)	50 (-82,181)	0.458
	Change since baseline	124	378(1314)	136	496(1341)	-118(-442,207)	0.477
Complimentary medicines	Pre-Treatment	168	124 (624)	167	110 (945)		
	Follow-Up	139	10 (88.14)	156	3 (40)	7 (-9,22)	0.393
	Change since baseline	136	55(456)	150	115(998)	-60(-244,123)	0.518
Religious Retreats	Pre-Treatment	167	390 (2208)	165	674 (3773)		
	Follow-Up	136	4 (43)	154	131 (655)	-127 (-238,-17)	0.024
	Change since baseline	131	432(2451)	145	626(4080)	-193(-983,596)	0.638
Total cost of all services	Pre-Treatment	172	3145 (14302)	174	2445 (6053)		
	Follow-Up	145	601 (694)	159	848 (1734)	-247 (-568,73)	0.130
	Change since baseline	145	2746 (15491)	159	1714 (6632)	1032(-1709,3774)	0.444
Total cost of intervention with international specialist supervisor[2]		172	17473 (912)	159	848 (1734)	16625 (16329,16922)	<.0001
Total cost of intervention with local specialist supervisor[3]		172	4151 (912)	159	848 (1734)	3303 (3007,3600)	<.0001

Table 2 shows costs of other services accessed by the participants. The data was collected using CSRI at baseline and 3 months' post-intervention follow-up assessment.

---

[2] Intervention costs plus cost of services. The cost of intervention with international supervisor is PKR 16,967
[3] Intervention costs plus cost of services. The cost of intervention with local supervisor is PKR 3,645

17

Table 3: Incremental Cost Effectiveness Ratios (ICERs) for PM+ intervention in PKR (1 USD = 104 PKR; 2016)

	International specialist supervisor		Local specialist supervisor	
Endpoint	Mean ICER	95% CI	Mean ICER	95% CI
HADS Anxiety	6172.99	[4575.49,8787.73]	1228.91	[882.86,1796.12]
HADS Depression	5704.27	[4384.51, 7651.85]	1135.81	[849.23,1561.68]
HADS Total	2957.45	[2261.64, 4029.00]	588.82	[434.01,820.27]
WHO DAS	4096.51	[2978.13, 6045.66]	815.89	[575.80,1225.10]
Depression caseness	53769.91	[39393.57, 77398.62]	10705.35	[7730.95,15627]

Note: (1) The cost was estimated after adjusting several baseline variables (baseline total cost, age, gender, occupation, marital status). (2) We used non-parametric bootstrapping to estimate confidence intervals with1000 resamples.

Abbreviations.; HADS = Hospital Anxiety and Depression Scales (subscale score range: 0-21; higher scores indicate elevated anxiety or depression, respectively); WHODAS = WHO Disability Assessment Schedule (total score range: 0-48; higher scores indicate more severe impairment); Depression caseness defined as (PHQ-9 cut-off 10 or above), PHQ = Patient Health Questionnaire

18

Figure 1a: Cost-effectiveness acceptability curve for PM+ with international supervisor (in PKR) (1 USD = 104 PKR; 2016)

Figure 1b: Cost-effectiveness acceptability curve for PM+ - with local trainer (in PKR) (1 USD = 104 PKR; 2016)

20

Figure 2a: Cost-effectiveness acceptability curve for PM+ with international supervisor (in PKR)
(1 USD = 104 PKR; 2016)

WHO DAS

Figure 2b: Cost-effectiveness acceptability curve for PM+ with local supervisor (in PKR) (1 USD = 104 PKR; 2016)

22

References:

1.   Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine J, Angermeyer MC, Bernert S, Morosini P, Polidori G: **Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys**. *JAMA* 2004, **291**(21):2581-2590.

2.   Saxena S, Thornicroft G, Knapp M, Whiteford H: **Resources for mental health: scarcity, inequity, and inefficiency**. *The Lancet* 2007, **370**(9590):878-889.

3.   Thornicroft G: **Most people with mental illness are not treated**. *The Lancet* 2007, **370**(9590):807-808.

4.   **Global Humanitarian Overview. Geneva, Switzerland: United Nations Office for the Coordination of Humanitarian Affairs** [https://interactive.unocha.org/publication/globalhumanitarianoverview/]

5.   Steel Z, Chey T, Silove D, Marnane C, Bryant RA, Van Ommeren M: **Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement: a systematic review and meta-analysis**. *JAMA* 2009, **302**(5):537-549.

6.   Roberts B, Browne J: **A systematic review of factors influencing the psychological health of conflict-affected populations in low-and middle-income countries**. *Global public health* 2011, **6**(8):814-829.

7.   Tol WA, Barbui C, Van Ommeren M: **Management of acute stress, PTSD, and bereavement: WHO recommendations**. *JAMA* 2013, **310**(5):477-478.

8.   Bangpan M, Lambert F, Chiumento A, Dickson K: **The impact of mental health and psychosocial support programmes for populations affected by humanitarian emergencies: a systematic review protocol**. 2016.

9.   Allden K, Jones L, Weissbecker I, Wessells M, Bolton P, Betancourt T, Hijazi Z, Galappatti A, Yamout R, Patel P: **Mental health and psychosocial support in crisis and conflict: report of the Mental Health Working Group**. *Prehospital and Disaster Medicine* 2009, **24**(S2):s217-s227.

10.   Rahman A, Riaz N, Dawson KS, Usman Hamdani S, Chiumento A, Sijbrandij M, Minhas F, Bryant RA, Saeed K, van Ommeren M: **Problem Management Plus (PM+): pilot trial of a WHO transdiagnostic psychological intervention in conflict-affected Pakistan**. *World Psychiatry* 2016, **15**(2):182-183.

11.   Sijbrandij M, Farooq S, Bryant RA, Dawson K, Hamdani SU, Chiumento A, Minhas F, Saeed K, Rahman A, Ommeren M: **Problem Management Plus (PM+) for common mental disorders in a humanitarian setting in Pakistan; study protocol for a randomised controlled trial (RCT)**. *BMC psychiatry* 2015, **15**(1):232.

12.   Rahman A, Hamdani SU, Awan NR, Bryant RA, Dawson KS, Khan MF, Azeemi MM-U-H, Akhtar P, Nazir H, Chiumento A: **Effect of a multicomponent behavioral intervention in adults impaired by psychological distress in a conflict-affected area of Pakistan: a randomized clinical trial**. *JAMA* 2016, **316**(24):2609-2617.

13.   Minhas F, Mubbashar M: **Validation of General Health Questionnaire (GHQ-12) in primary care settings of Pakistan**. *J Coll Physicians Surg Pak* 1996, **6**:133-136.

14.   WHO: **Section 8 Syntax for automatic computation of overall score using SPSS: Measuring health and disability-Manual for WHO disability assessment schedule WHODAS 2.0**: World Health Organization; 2010.

23

15.   Dawson KS, Bryant RA, Harper M, Kuowei Tay A, Rahman A, Schafer A, van Ommeren M: **Problem Management Plus (PM+): A WHO transdiagnostic psychological intervention for common mental health problems**. *World Psychiatry* 2015, **14**(3):354-357.

16.   McEvoy PM, Nathan P, Norton PJ: **Efficacy of transdiagnostic treatments: A review of published outcome studies and future research directions**. *Journal of Cognitibe Psychology* 2009, **23**(1):20-33.

17.   World Health Organization: **Problem Management Plus (PM+): Individual Psychological Help for Adults Impaired by Distress in Communities Exposed to Adversity (Generic Field-Trial Version 1.0).** In*.* Geneva, Switzerland:World Health Organization; 2016.

18.   Zigmond AS, Snaith RP: **The hospital anxiety and depression scale**. *Acta Psychiatrica Scandinavica* 1983, **67**(6):361-370.

19.   Mumford D, Tareen I, Bajwa M, Bhatti M, Karim R: **The translation and evaluation of an Urdu version of the Hospital Anxiety and Depression Scale**. *Acta Psychiatrica Scandinavica* 1991, **83**(2):81-85.

20.   Kroenke K, Spitzer RL, Williams JB: **The PHQ-9: validity of a brief depression severity measure**. *Journal of general internal medicine* 2001, **16**(9):606-613.

21.   **The PTSD Checklist for DSM-5 (PCL-5)** [http://www.ptsd.va.gov/professional/assessment/adult-sr/ptsd-checklist.asp.]

22.   Chisholm D, Knapp MRJ, Knudsen HC, Amaddeo F, Gaite L, Van Wijngaarden B, Group ES: **Client socio-demographic and service receipt inventory–European version: development of an instrument for international research: EPSILON Study 5**. *British Journal of Psychiatry* 2000, **177**(S39):s28-s33.

23.   Patel V, Weiss HA, Chowdhary N, Naik S, Pednekar S, Chatterjee S, De Silva MJ, Bhat B, Araya R, King M: **Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial**. *The Lancet* 2010, **376**(9758):2086-2095.

24.   Mccrone P, Knapp M, Proudfoot J, Ryden C, Cavanagh K, Shapiro DA, Ilson S, Gray JA, Goldberg D, Mann AJTBJoP: **Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial**. *European Journal of Psychotraumatology* 2004, **185**(1):55-62.

25.   Khan I: **Design & Analysis of clinical trials for Economic Evaluation & Reimbursement: an applied approach using SAS & STATA**: Chapman and Hall/CRC; 2015.

26.   Baltussen RM, Hutubessy RC, Evans DB, Murray CJJIjotaihc: **Uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables**. *International Journal of technology Assessment in Health Care* 2002, **18**(1):112-119.

27.   Fenwick E, Marshall DA, Levy AR, Nichol GJBhsr: **Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation**. *BMC Health Services Research* 2006, **6**(1):52.

28.   Little RJ, Rubin DB: **Statistical analysis with missing data**, vol. 793: John Wiley & Sons; 2019.

29.   Govt. of Pakistan Finance Division Islamabad: **Federal Budget** In*.*; 2017.

30.   Buttorff C, Hock RS, Weiss HA, Naik S, Araya R, Kirkwood BR, Chisholm D, Patel V: **Economic evaluation of a task-shifting intervention for common mental disorders in India**. *Bulletin of the World Health Organization* 2012, **90**(11):813-821.

31.   Weobong B, Weiss HA, McDaid D, Singla DR, Hollon SD, Nadkarni A, Park A-L, Bhat B, Katti B, Anand A *et al*: **Sustained effectiveness and cost-effectiveness of the Healthy Activity Programme, a brief psychological treatment for depression delivered by lay counsellors in primary care: 12-month follow-up of a randomised controlled trial**. *Plos Medicine* 2017, **14**(9):e1002385.

32. Murray LK, Dorsey S, Bolton P, Jordans MJ, Rahman A, Bass J, Verdeli H: **Building capacity in mental health interventions in low resource countries: an apprenticeship model for training local providers**. *International Journal of Mental Health Systems* 2011, **5**(1):30.

33. Chisholm LCa: **Cost-Effectiveness and Affordability of Interventions, Policies, and Platforms for the Prevention and Treatment of Mental, Neurological, and Substance Use Disorders, In, Mental, Neurological, and Substance Use Disorders**, vol. 4, 3 edn. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2016.

34. Araya R, Flynn T, Rojas G, Fritsch R, Simon G: **Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile**. *American journal of psychiatry* 2006, **163**(8):1379-1387.

35. Sikander S, Ahmad I, Atif N, Zaidi A, Vanobberghen F, Weiss HA, Nisar A, Tabana H, Ain QU, Bibi A *et al*: **Delivering the Thinking Healthy Programme for perinatal depression through volunteer peers: a cluster randomised controlled trial in Pakistan**. *Lancet Psychiatry* 2019, **6**(2):128-139.

36. Ventevogel P, van Ommeren M, Schilperoord M, Saxena S: **Democratic Republic of the Congo»**. *J Bulletin of the World Health Organization* 2015, **93**:666-666A.

Figure 1a: Cost-effectiveness acceptability curve for PM+ with international supervisor (in PKR) (1 USD = 104 PKR; 2016)

Figure 1b: Cost-effectiveness acceptability curve for PM+ - with local trainer (in PKR) (1 USD = 104 PKR; 2016)

WHO DAS

Figure 2a: Cost-effectiveness acceptability curve for PM+ with international supervisor (in PKR) (1 USD = 104 PKR; 2016)

114x88mm (150 x 150 DPI)

WHO DAS

Figure 2b: Cost-effectiveness acceptability curve for PM+ with local supervisor (in PKR) (1 USD = 104 PKR; 2016)

114x88mm (150 x 150 DPI)